Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 18/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939403 | 0.93 | SCNN1A (0.42) | SCNN1A | |
| SCHEMBL939066 | 0.91 | SCNN1A (0.48) | SCNN1A | |
| SCHEMBL4660316 | 0.87 | SCNN1A (0.46) | SCNN1A | |
| SCHEMBL12908918 | 0.85 | SCNN1A (0.45) | SCNN1APOLB | |
| SCHEMBL937248 | 0.85 | SCNN1A (0.45) | SCNN1APOLB | |
| SCHEMBL937899 | 0.84 | SCNN1A (0.49) | SCNN1A | |
| SCHEMBL938196 | 0.83 | SCNN1A (0.49) | SCNN1A | |
| SCHEMBL938701 | 0.83 | SCNN1A (0.44) | SCNN1A | |
| SCHEMBL2329797 | 0.83 | SCNN1A (0.51) | SCNN1ACA1CA2 | |
| SCHEMBL5720717 | 0.82 | SCNN1A (0.44) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1599096-B1 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1599096-A4 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | SCNN1A 59/4885CA1 2788/4885CA2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.